T1	p 43 121	early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy .
T2	p 320 359	Type 2 diabetic patients ( N.=57 ) were
T3	p 373 479	two groups as with nephropathy ( N.=27 ) and without nephropathy ( N.=30 ) . Diabetic nephropathy patients
T4	p 841 860	diabetic group with
T5	p 1355 1427	2 diabetes mellitus patients with nephropathy than without nephropathy .
T6	i 13 25	AGE-peptides
T7	i 101 119	pyridoxine therapy
T8	i 163 186	circulatory AGE-peptide
T9	i 248 311	thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .
T10	i 505 557	B6 ( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250
T11	i 572 573	)
T12	i 1075 1077	B6
T13	o 13 39	AGE-peptides and C-peptide
T14	o 175 193	AGE-peptide levels
T15	o 653 766	glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate
T16	o 1196 1241	increase in C-peptide ( P=0.006 , P=0.004 ) .
T17	o 1285 1304	plasma AGE-peptides
T18	o 1529 1541	AGE-peptides
T19	o 1605 1619	in C-peptide .